Conditions: Liver Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 51
Healthy volunteers: no

Brief summary:
This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer. Patients were treated with Tarceva 150 mg po daily plus Avastin 5 mg/kg intravenous (iv) every 2 weeks. The anticipated time on study treatment was until disease progression, and the target sample size was \<100 individuals.

Detailed description:

Arms:
arm 1: Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression or unmanageable toxicity.

Interventions: intervention 1: bevacizumab (Avastin) intervention 2: erlotinib (Tarceva)
Intervention descriptions: intervention 1: 5 mg/kg iv on day 1 of each 2 week cycle. intervention 2: 150 mg orally (po) daily.

Protocol document: